Ganaplacide/ lumefantrine
Small molecule
Also known as KLU156
Evidence outlook · registrational
Malaria: topline reported 2025-11-12
No completed mid-stage readout is on record. The sponsor reported topline results on 2025-11-12 (Phase III KALUMA trial of GanLum meets primary endpoint). The announcement is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Malaria: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ganaplacide / Lumefantrine: this drug | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Cipargamin | Phase 2 | Small molecule | PfATP4 | not yet graded | No reviewed efficacy summary in this indication | |
| GSK3772701 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4024484 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| INE963 | Phase 1(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4425689 | —(overall) | Undisclosed | Circumsporozoite protein (CSP) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ganaplacide/lumefantrine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
February 2027 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent